KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
CT staging performance in an international trial of neoadjuvant chemotherapy for locally advanced colon cancer. PMID 40848246 · Br J Radiol · 2025-Dec-01 The record is from a randomized trial with a drug intervention but does not report on a time-to-event efficacy endpoint. It is a secondary analysis of staging accuracy, not a primary or key secondary efficacy result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypofractionated stereotactic radiotherapy versus whole-brain radiotherapy following brain metastasis resection: Results of the ESTRON randomized phase 2 trial. PMID 40747537 · Neuro Oncol · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trial. PMID 40568722 · Haematologica · 2025-Dec-01 The record describes a randomized trial with time-to-event efficacy endpoints (EFS, OS) and a drug intervention (blinatumomab). However, the provided metadata does not explicitly confirm the trial phase as Phase III, Phase IIIb, or Phase II/III. The deterministic review signals 'phase3': false and 'phase3_publication_type': false. As per instructions, the phase must be explicitly established from the metadata to be eligible for inclusion; it cannot be inferred. Therefore, the record is excluded due to the lack of confirmed definitive phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis. PMID 40071779 · Am J Gastroenterol · 2025-Dec-01 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Trial. PMID 39996303 · Ann Surg · 2025-Dec-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Study Protocol for a Randomized Clinical Trial Investigating the Effect of Reduced Bleomycin in Electrochemotherapy Treatment on Patients with Cutaneous Metastases (The BLESS Trial). PMID 42428808 · Bioelectricity · 2025-Dec 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A barrier-forming gel for oral mucositis in head and neck cancers patients undergoing radiotherapy: randomized, controlled, multicenter trial. PMID 41497518 · EClinicalMedicine · 2025-Dec The intervention is a non-drug (barrier-forming gel/device), which is excluded by the criteria. The trial phase is also not explicitly confirmed as Phase III/II in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and patient's satisfaction of preoperative carbohydrate drink until 2 hours before colorectal cancer surgery: a single-center, prospective randomized controlled trial. PMID 41486909 · Ann Coloproctol · 2025-Dec The record describes a randomized trial in colorectal cancer surgery patients, but it does not meet key eligibility criteria: it lacks a drug intervention (the intervention is a non-drug carbohydrate drink), it does not report a time-to-event efficacy endpoint (it focuses on satisfaction, safety, and perioperative outcomes), and it is not a definitive Phase III/IIIb or Phase II/III efficacy trial. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Statins Reduce Wall Enhancement at Vessel Wall MRI in Unruptured Vertebrobasilar Dissecting Aneurysms: A Randomized Controlled Trial. PMID 41432563 · Radiology · 2025-Dec The study is a randomized controlled trial of atorvastatin in unruptured vertebrobasilar dissecting aneurysms. It is not oncology-related, as it focuses on a vascular condition, not malignant neoplasms. While it meets criteria for being human, randomized, drug-intervention, and original-result, it fails the core oncology and time-to-event endpoint requirements.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intensified pegylated-asparaginase in consolidation therapy improved outcome of allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia. PMID 41430506 · Ann Hematol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparison of the Clinical Response in Total Neoadjuvant Treatment With Long-Term or Short-Term Chemoradiotherapy Followed by Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer (TEHRAN); the Protocol for a Randomized Controlled Clinical Trial. PMID 41412957 · Cancer Med · 2025-Dec 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial. PMID 41359669 · PLoS Med · 2025-Dec 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial. PMID 41324016 · EClinicalMedicine · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China. PMID 41324015 · EClinicalMedicine · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preliminary Outcomes of a Culturally Adapted Fear of Recurrence Therapy (FORT) for Turkish Breast Cancer Survivors: A Randomized Controlled Trial. PMID 41318944 · Psychooncology · 2025-Dec The study is an oncology, human, randomized trial reporting original results. However, it is excluded because: 1) The intervention is a non-drug psychological therapy (FORT), not a drug-containing intervention. 2) The primary and secondary outcomes are psychological and quality-of-life measures (FCR, anxiety, depression, etc.), not the required time-to-event efficacy endpoints (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry. PMID 41313970 · ESMO Open · 2025-Dec Eligible. This is a final report of a randomized trial in HR-positive early breast cancer with drug-containing chemotherapy arms, reporting 10-year time-to-event efficacy endpoints (iDFS, dDFS, OS). The trial is described as a randomized controlled trial. The registry follow-up provides final long-term results from the original randomized PlanB trial. The phase is inferred as definitive (Phase III) from the context of a randomized trial with standard chemotherapy arms, though not explicitly stated in metadata.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 6 Panel · risk visible
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX). PMID 41313969 · ESMO Open · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer. PMID 41311332 · J Breast Cancer · 2025-Dec The record describes a registered randomized trial protocol for a surgical intervention (omission of sentinel lymph node biopsy) after neoadjuvant systemic therapy. It reports no results. The phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the intervention is not a drug (it is a comparison of surgical procedures). Therefore, it is not an eligible report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Double-Blind Randomized Sham-Controlled Trial of Two Online Cognitive Bias Modification Interventions for Fear of Cancer Recurrence in People With Breast or Ovarian Cancer. PMID 41310810 · Psychooncology · 2025-Dec The study is a randomized oncology trial with original results, but it does not meet eligibility because it lacks a time-to-event efficacy endpoint and uses a non-drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. PMID 41308679 · Lancet Oncol · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort. PMID 41297161 · ESMO Open · 2025-Dec The record describes a retrospective real-world cohort study evaluating the pathological complete response (pCR) rate of a regimen used in a prior Phase III trial. It is not an original report of a randomized Phase III trial, and its primary endpoint (pCR) is not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Minimally Invasive versus Open Pancreatoduodenectomy for Resectable Neoplasms. PMID 41288428 · NEJM Evid · 2025-Dec 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Can Prostate Cancer Screening Reduce Mortality in Men Aged 75-79 Years? A Protocol for Target-trial Emulation. PMID 41280154 · Eur Urol Open Sci · 2025-Dec 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluating Circulating Tumor DNA Clearance as an Early Intermediate End Point Predicting Clinical Benefit in Metastatic Nonsquamous NSCLC After First-Line Chemoimmunotherapy. PMID 41278397 · JTO Clin Res Rep · 2025-Dec The report is a secondary analysis using data from a Phase III trial (IMpower150) to evaluate ctDNA clearance as a surrogate endpoint. It is not the original, primary, or formal result report of the randomized trial itself, which would present the trial's primary efficacy outcomes. The deterministic review correctly identified the lack of explicit randomization evidence in this secondary analysis, but the more fundamental exclusion is that this is not the trial's result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial. PMID 41245547 · EClinicalMedicine · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non-small cell lung cancer: a prospective phase II study (GASTO-1053). PMID 41235462 · Cancer Commun (Lond) · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study. PMID 41232542 · Lancet Oncol · 2025-Dec The record is excluded because it is not a randomized trial, does not involve a drug intervention, and lacks a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of gum chewing on the return of bowel sounds, time to first flatus, and defecation after colorectal cancer surgery: A prospective, randomized controlled trial. PMID 41232231 · Eur J Oncol Nurs · 2025-Dec Study is a randomized trial in human colorectal cancer patients, but the intervention is non-drug (gum chewing) and the primary endpoints are postoperative recovery of bowel function, not a standard oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer. PMID 41230651 · Future Oncol · 2025-Dec Phase III drug trial with time-to-event endpoints, but the provided metadata does not explicitly establish randomization, which is a required criterion for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy of Tegafur-Uracil Maintenance Therapy in Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Meta-Analysis With Trial Sequential Analysis. PMID 41208841 · World J Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34. PMID 41197528 · Breast · 2025-Dec The record describes a secondary analysis of biomarker concordance and prognostic value within a randomized trial (ABCSG Trial 34), but does not specify a drug-containing intervention or its efficacy. The primary objective is diagnostic assay validation, not a drug treatment comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy. PMID 41192094 · Lung Cancer · 2025-Dec The record is an analysis of outcomes from a screening trial cohort comparing surgery vs. SABR for stage I lung cancer. It is oncological, human, randomized (within the screening trial context), reports time-to-event endpoints (OS, CSS), and is an original result. However, it is excluded because it does not involve a drug-containing intervention (surgery and SABR are non-drug modalities) and does not represent a Phase III/IIIb or Phase II/III randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial. PMID 41175808 · Breast · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Image-guided surgical navigation for inguinal sentinel lymph node procedures in vulvar cancer. PMID 41161157 · Int J Gynecol Cancer · 2025-Dec Study is a randomized feasibility trial in vulvar cancer but lacks required Phase III/IIIb status, drug intervention, and time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Variable Selection via Fused Sparse-Group Lasso Penalized Multi-state Models Incorporating Molecular Data. PMID 41146443 · Biom J · 2025-Dec The record is a methodological/statistical paper that applies a new algorithm to AML trial data, not a report of the trial's clinical efficacy results. While it references a Phase III RCT, the abstract does not contain the formal results of a time-to-event efficacy endpoint. Therefore, it is excluded as not being an original result report of trial efficacy.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer. PMID 41116141 · Adv Ther · 2025-Dec The record describes a secondary, operational efficiency analysis (time-and-motion study) conducted alongside a phase 3 trial. It does not report the trial's primary or key secondary time-to-event efficacy outcomes (e.g., OS, PFS) and is therefore ineligible for a Kaplan-Meier digitization cohort focused on efficacy endpoints.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. PMID 41109919 · Nat Med · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pre-Operative Resistance Training and Amino Acid Supplementation in Frail Patients With Gastrointestinal Cancer: A Randomized Clinical Trial. PMID 41108598 · Geriatr Gerontol Int · 2025-Dec The study is a randomized clinical trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III trial, the intervention is non-drug-only (resistance training and amino acid supplementation), and the primary endpoints are postoperative complications and physical function, not time-to-event oncology efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ten-year outcomes of 3D-conformal accelerated partial vs. whole breast irradiation after breast-conserving surgery: A randomized study from India. PMID 41106124 · Surg Oncol · 2025-Dec The study is a randomized oncology trial with time-to-event endpoints, but it does not involve a drug-containing intervention and the trial phase is not explicitly defined as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. PMID 41083802 · Dermatol Ther (Heidelb) · 2025-Dec The record describes a protocol for a Phase 3 trial in alopecia areata (a non-malignant condition). The primary endpoint is a categorical response (SALT score ≤20), not a time-to-event endpoint like OS, PFS, or TTP. It does not report results; it is a protocol/design paper.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial. PMID 41062829 · Nat Med · 2025-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction (ENDURO): a randomised controlled trial. PMID 41061719 · Lancet Gastroenterol Hepatol · 2025-Dec The trial is a randomized, oncology study with a time-to-event primary endpoint, but it does not involve a drug-containing intervention (comparing two surgical/endoscopic procedures). Additionally, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial. PMID 41057084 · Radiother Oncol · 2025-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of sacral nerve magnetic stimulation in preventing urinary retention after total hysterectomy: a randomised controlled trial. PMID 41051260 · J Obstet Gynaecol · 2025-Dec The study is a randomized controlled trial in a surgical population for gynecological malignancies, but it does not meet key eligibility criteria: (1) The intervention is sacral nerve magnetic stimulation (non-drug), not a drug-containing intervention. (2) The primary endpoint is incidence of postoperative urinary retention, not a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio. (3) The phase of the trial is not specified as Phase III/IIIb or Phase II/III, and given the nature of the intervention (device/physical therapy), it is not a definitive oncology drug trial. The report is an original primary result but is excluded based on these fundamental mismatches with the cohort definition.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial. PMID 41045868 · Semin Arthritis Rheum · 2025-Dec The study is a randomized, double-blind, placebo-controlled trial in rheumatoid arthritis, which is not an oncology (malignant neoplasm) indication. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. PMID 41043449 · Lancet Gastroenterol Hepatol · 2025-Dec 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial. PMID 41036595 · Am J Hematol · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ifupinostat: First Approval. PMID 41028651 · Drugs · 2025-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A randomized prospective trial comparing Bacillus Calmette-Guérin (BCG) RIVM and Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects. PMID 41006133 · Urol Oncol · 2025-Dec The record meets criteria for being an original, randomized, oncology trial with time-to-event endpoints and a drug intervention. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, which is a required inclusion criterion. Therefore, it cannot be confirmed as eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation. PMID 40990091 · Am J Hematol · 2025-Dec Although the record mentions a Phase III registration trial (NCT01696084) and includes oncology, human, Phase III, time-to-event, and drug intervention signals, the specific report provided is a retrospective real-world study, not a report of the original randomized trial results. It lacks evidence of being a randomized trial itself.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -